Psychiatrists published a very special article on the beneficial effects of palmitoylethanolamide on autism, based on observations in 2 patients.
They point out that there is a growing body of evidence indicating that inflammatory mediators may contribute to autism. Because palmitoylethanolamide (PEA) is naturally occurring anti-inflammatory agent, and because it is available as neutraceutical PEA has already been tested in thousands of human subjects without any noted significant side effects.
The authors report the first cases of the administration of PEA to two children with autism.
The first 13-year-old male child presented significant eczema and allergies. Expressive language and overall autism severity as measured by the Childhood Autism Rating Scale, improved significantly after administration of PEA. The atopic symptoms also diminished. No side effects were reported.
The second autistic male child, age 15, was also treated with PEA had rapid improvements in cognitive, behaviors, and sociability.
The authors concluded: “Palmitoylethanolamide could be an effective treatment for autism syndrome.”
Due to the fact that there are no clinical relevant side effects of PEA, parents should be aware of the possibility to treat their children with such a harmless neutraceutical.
Antonucci N, Cirillo A, Siniscalco D. Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases.
Case Rep Psychiatry. 2015;2015:325061.
Friedrich MJ (2014) Research on Psychiatric Disorders Targets Inflammation. JAMA Medical News & Perspectives July 23, 2014